NASDAQ:TEM Stock Quote

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7-10, 2025.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NYSE:TDOC),(NASDAQ:TALK),(NASDAQ:BFRG) EQNX::TICKER_END

PALM BEACH, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial intelligence (AI) has become a significant part of healthcare and is being used in almost all sectors, including diagnostics. The integration of AI has increased the growth and development of the healthcare industry. In diagnostic testing, AI is used to analyze medical images (CT scans, X-rays, ultrasounds, MRIs, and DXAs), large patient data, vital signs (pulse rate, body temperature, blood pressure, and respiration rate), medical history, and laboratory test results. AI provides several advantages in diagnostics, such as accuracy, efficiency, reduced human errors, and cost savings. Healthcare professionals can make more informed decisions and develop personalized treatment options. The AI in the diagnostics market is growing due to reduced healthcare costs, reduced healthcare burden on professionals, and enhanced patient satisfaction. A recent report from Towards Healthcare, said: “The global AI in diagnostics market is to value at US$ 1.74 billion in 2025 is to touch US$ 5.24 billion by 2030. In 2023, North America led the AI in diagnostics market with a 53% share, while Asia Pacific is set to experience the fastest growth. The software segment dominated by component and is expected to show the highest CAGR. In diagnosis, neurology held the largest market share, while radiology is predicted to grow at the quickest pace during the forecast period. AI in diagnostics is advancing accuracy and efficiency in medical evaluations, driving its global expansion across various sectors.”   Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), Teladoc Health (NYSE: TDOC), Talkspace (NASDAQ: TALK), BullFrog AI Holdings, Inc. (NASDAQ: BFRG).

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies.

PALM BEACH, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - A report from Fortune Business Insights said that the global artificial intelligence in healthcare market size is projected to grow from USD 27.69 billion in 2024 to USD 490.96 billion by 2032, exhibiting a CAGR of 43.2% during the forecast period. The report added: “AI in healthcare market in the U.S. is experiencing rapid expansion, driven by the increasing adoption of AI-powered solutions for diagnostics, personalized treatment, and administrative automation. North America dominated the AI in the healthcare market with a market share of 44.93% in 2023. Artificial Intelligence in healthcare is used to analyze the medical data that helps doctors and medical providers deliver accurate diagnoses and treatments to their patients. AI in healthcare assists doctors, nurses, and other healthcare workers to enhance their productivity. This advancement helps patients in treatment and improves their quality of life. Also, according to an article published by GE Healthcare, it is found that healthcare professionals are already using AI to improve data analysis, which has enabled them to diagnose their patients in a better way with proper predictions for the treatment and decrease the time spent by the medical staff on administrative functioning.” Active companies active in the healthcare markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), Teladoc Health (NYSE: TDOC), Aclarion, Inc. (NASDAQ: ACON), Medtronic plc (NYSE:MDT).

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NYSE:TDOC),(NASDAQ:ACON),(NYSE:MDT) EQNX::TICKER_END

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health Care Conference on March 3-5, 2025 in Boston, MA.

Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent on $300 million in incremental debt financing for Tempus AI, Inc. (NASDAQ: TEM) (“Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care. The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics (“Ambry”), which closed on February 3, 2025. Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom Conference on Monday, March 3-6, 2025, held in San Francisco, CA.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). The collaboration aims to develop and make available a real-world multimodal, deidentified FL data library in Lens - Tempus’ data analytics platform - through which researchers may derive AI-driven insights to accelerate the development of FL treatments in an effort to improve patient outcomes.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NYSE:BBAI),(NASDAQ:TALK),(NASDAQ:SOUN) EQNX::TICKER_END

PALM BEACH, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The growing adoption of the digital technologies in the healthcare sector owing to the growing need for reducing the healthcare costs and offer enhanced quality patient care services to the patients are the prominent factors that are boosting the growth of the global artificial intelligence in healthcare market. The surging prevalence of various chronic diseases and growing elderly population is resulting in the increased pool of patients at hospitals. The large volume of patient health data is generated every day, which is required to be stored and managed effectively. The growing demand for the personalized medicines and the necessity of maintaining digital health records are significantly driving the artificial intelligence in healthcare market. The novel technologies like artificial intelligence and machine learning are now being integrated to the healthcare systems that will allow the health professionals in early identification of the diseases and offer enhanced care services to the patients. Moreover, the data analytics, deep learning technology, natural language processing (NPL), predictive analytics, and content analytics are supporting the healthcare professionals in early diagnosis and care services. A report from Precedence Research said that the global artificial intelligence (AI) in healthcare market size accounted for USD 26.69 billion in 2024 and is predicted to reach around USD 613.81 billion by 2034, growing at a CAGR of 36.83% from 2024 to 2034. North America AI in healthcare market size reached USD 8.67 billion in 2023. Active A.I. companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), BigBear.ai (NYSE: BBAI), Talkspace (NASDAQ: TALK), SoundHound AI, Inc. (NASDAQ: SOUN).

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NYSE:MDT),(NYSE:TDOC),(NASDAQ:TALK) EQNX::TICKER_END

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels available.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision support in the clinic while simultaneously advancing research to bring new drugs to market. This latest iteration now applies Tempus’ proprietary Large Language Model (LLM) Agent Infrastructure (Agent Builder), which adapts LLMs to work on unstructured, multimodal healthcare data to improve clinical care and research.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus’ first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan Healthcare on January 13-16, 2025, in San Francisco, CA.

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END

Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. As part of the agreement with Avalon, Tempus is a participating provider with BCBS North Carolina, BCBS South Carolina, BCBS Vermont, Capital BlueCross and CareSource in four markets. This enhances our work with commercial health plans in the East.